The fair value estimate for Alnylam Pharmaceuticals is 97% higher than analysts' price target. A Discounted Cash Flow (DCF) model is used to evaluate the company's investment potential. The valuation method considers future cash flows and discounting them to present value.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing